Skip to main content
    C

    Candel Therapeutics Inc (CADL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $5.81
    -0.39 (-6.29%)

    Market Cap: $486.37M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    48%(10/21)
    Avg Surprise
    -6.20%
    Streak
    1 Q

    Upcoming Estimates

    Reports Mar 10, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.38
    Range-$0.60 - -$0.08
    12 analysts
    Revenue Consensus
    N/A
    RangeN/A
    11 analysts
    Reports May 12, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.32
    Range-$0.32 - -$0.32
    1 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.00n/a
    60d ago$0.00n/a
    30d ago-$0.320.0%
    7d ago-$0.320.0%
    Current-$0.32
    Revenue Consensus
    N/A
    RangeN/A
    2 analysts

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCF-6.40xFCF Yield-15.61%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-93.60%ROIC-43.46%
    Financial Health
    Debt/Equity0.37xInterest Coverage-16.09x
    Current Ratio7.57xQuick Ratio7.57x
    Trading Statistics
    Beta-0.29Avg Volume1.51M
    52-Week High$14.0052-Week Low$4.35

    Technical Indicators Dashboard

    As of Nov 16, 2026, the price is 39.6% below its 50-day moving average, and the 50-day average is above the 200-day average. The 14-day RSI is 29.2, below 30, the oversold line.

    Moving Averages

    SMA 10$8.31
    SMA 20$8.32
    SMA 50$9.61
    SMA 200$8.40
    EMA 10$7.88
    EMA 20$8.36
    EMA 50$9.25
    EMA 200$8.73

    MACD

    Line: -0.59Signal: -0.43Hist: -0.17

    ADX

    ADX: 30.3+DI: 14.3-DI: 45.5

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down96.0
    PSAR$9.75

    Bollinger Bands

    Upper Band$10.14
    Lower Band$6.49
    %B Position4390%(Upper)
    Band Width-0.19

    RSI (14-Day)

    Oversold
    29.2

    Momentum Oscillators

    Stoch %K22.3
    Stoch %D41.3
    Williams %R-86.9
    ROC (10d)-28.4%
    Momentum-2.31
    CCI (20d)-285.5
    MFI (14d)41.0

    Volatility Measures

    ATR (14d)$0.81(14.0%)
    StdDev (20d)0.91
    Hist Vol129.7%(High)

    Volume Flow

    VWAP$5.92
    OBV9.0M
    AD Line-18.7M
    CMF (20d)-0.017

    Volume Metrics

    Avg Vol (20d)1.5M
    Vol Ratio2.1x(High)
    VWMA (20d)$7.78

    Pivot Points

    R3$8.25
    R2$7.44
    R1$6.82
    Pivot Point$6.01
    S1$5.39
    S2$4.58
    S3$3.96

    Advanced Oscillators

    TSI-20.70
    Ultimate Osc40.9
    KST-132.23

    Financial Performance

    Related GNG Research

    No research available

    Be the first to write about CADL

    News

    CADL Valuation

    Candel Therapeutics (CADL) trades at 43.5x forward earnings.

    Forward P/E
    43.5x
    P/FCF
    -6.4x
    P/B
    3.4x
    All CADL metrics

    CADL Profitability: Margins, ROIC and FCF

    Candel Therapeutics (CADL) has an operating margin of 0.0% and a net margin of 0.0%. It posts -43.5% ROIC.

    Operating margin
    0.0%
    Net margin
    0.0%
    ROIC
    -43.5%
    ROE
    -93.6%
    FCF yield
    -15.6%
    CADL financial statements

    Candel Therapeutics Competitors

    The companies most similar to Candel Therapeutics (CADL) include CytomX Therapeutics, Century Therapeutics and Indaptus Therapeutics.

    Sector: Healthcare

    Companies most similar to Candel Therapeutics

    CADL Analyst Ratings

    Candel Therapeutics (CADL) has a Buy consensus from 10 analysts: 10 Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell.

    Consensus
    Buy
    Analysts
    10
    Strong Buy
    0
    Buy
    10
    Hold
    0
    Sell
    0
    Strong Sell
    0
    CADL stock forecast

    CADL Bull Case vs Bear Case

    Bull case

    • 100.0% of CADL's analyst ratings are Buy or Strong Buy.

    Bear case

    • CADL beat EPS estimates in 37.5% of its last 8 reported quarters.

    CADL Earnings: Beat Rate and Next Report

    Candel Therapeutics (CADL) beat the EPS estimate in 3 of the last 8 quarters (37.5%). Its next report is expected on Mar 10, 2027.

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -8.1%
    EPS estimate (fiscal period ending Dec 31, 2026)
    -$0.38
    CADL earnings history

    CADL Earnings Date

    CADL reports Mar 10, 2027. The date is estimated.

    CADL ETF Holders

    See insider activity

    Updated Nov 12, 2026. Built from end-of-day prices, company filings and consensus analyst estimates. Methodology

    Frequently Asked Questions About CADL

    When does CADL report earnings?

    Candel Therapeutics Inc (CADL) is expected to report earnings on Mar 10, 2027.

    Does CADL pay dividends?

    Candel Therapeutics Inc (CADL) does not currently pay a regular dividend.

    What is CADL's market cap?

    Candel Therapeutics Inc (CADL) has a market capitalization of $486.37M with a current stock price of $5.81.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.